Sign in Create account

Supriya Lifescience Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: SUPRIYA BSE: 543434
₹950.25
▼ -34.80 (-3.53%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
65/100
Moderate
Valuation
1/100
Expensive
Momentum
86/100
Bullish

QVM read Momentum-led Quality Moderate, Valuation Expensive, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹7,648 Cr
PE (TTM)
38.5
Industry median 36.1 (152 companies)
Price to Book
6.4
PEG (TTM)
3.4
Institutions holding %
11.49%
FII + DII, latest filed period
Piotroski Score
4
Relative return vs Nifty50, qtr %
-2.5
Relative return vs Sector, qtr %
-5.9
Free Cash Flow
₹34 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-30.79%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
11.38%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
28.14%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-30.89%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
30.79%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
4.40
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.00
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
154.15
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
12.67%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
21.70%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
30.93%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
15.41%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
22.38%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
17.46%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

4 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 4)
  • Yes Debt to equity is below 0.5 (0.00)
  • Yes Return on equity is 15% or more (17.5%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

2 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Sell Zone)
  • No Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-3.5%
Low 945.2000 · High 995.9500
1W return
-5.1%
Low 945.2000 · High 1019.8000
1M return
19.0%
Low 795.5000 · High 1019.8000
52W return
29.6%
Low 545.5000 · High 1085.0000
Lifetime High ₹1052.5000 (June 1, 2026)
Lifetime Low ₹175.9500 (March 28, 2023)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish4
Bearish2
5D
967.2
10D
954.3
20D
925.3
50D
887.1
100D
852.6
200D
772.5

Delivery and volume

Day avg. delivery
48.7%
Week avg. delivery
38.0%
Month avg. delivery
36.6%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

963.80
Pivot
First resistance982.40
Second resistance1014.55
Third resistance1033.15
First support931.65
Second support913.05
Third support880.90
Day RSI57.2
Day MFI78.7
Day MACD34.57
Day MACD signal29.74

Beta

1M2.45
3M0.29
1Y0.71
3Y1.14

Price change analysis

↑ 19.0%
Over 1 Month
LowHigh
795.501019.80
↓ -5.9%
Over 3 Months
LowHigh
740.451038.60
↑ 58.1%
Over 6 Months
LowHigh
583.951085.00
↑ 29.6%
Over 1 Year
LowHigh
545.501085.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 38.5 (own history: 21.6–41.3)
Sell Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹190 Cr
Net profit (June 30, 2026)
₹24 Cr
Basic EPS (June 30, 2026)
₹2.9900

Ranks #49 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter68.30%
  • Mutual funds1.29%
  • FII/FPI6.19%
  • Other DII4.01%
  • Public20.21%

Largest holders

NameCategoryShares %Shares
Satish Waman WaghPromoter67.6400%54441205
Cohesion Mk Best Ideas Sub-TrustPublic2.9800%2401769
Aditya Birla Sun Life Insurance Company LimitedPublic2.1900%1761150
Smita Satish WaghPromoter0.4000%321750
Saloni Satish WaghPromoter0.1300%102375

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 68.30% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 5.16% to 6.19% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 1.33% to 1.29% in Jun 2026 qtr

2 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 8 insider trades, 6 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
28 Feb 2024 Shivani Satish Wagh Promoter group Buy 0 ₹0
28 Feb 2024 Saloni Satish Wagh Promoter group Sell 0 ₹0
3 Apr 2023 Satish Waman Wagh Promoter Buy 0 ₹0
31 Mar 2023 Satish Waman Wagh Promoter Buy 0 ₹0
6 Mar 2023 Satish Waman Wagh Promoter Buy 0 ₹0
6 Mar 2023 Satish Waman Wagh Promoter Buy 0 ₹0
2 Mar 2023 Satish Waman Wagh Promoter Buy 0 ₹0
2 Mar 2023 Satish Waman Wagh Promoter Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 19 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
22 Nov 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 585,068 784.7900 NSE
22 Nov 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 585,068 785.0200 NSE
12 May 2023 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 403,147 248.3800 NSE
12 May 2023 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 403,147 248.4800 NSE
27 Mar 2023 DOVETAIL INDIA FUND CLASS 6 SHARES Bulk Sell 547,398 177.0800 NSE
24 Jan 2022 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 487,816 460.5200 NSE
24 Jan 2022 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 487,816 460.0300 NSE
29 Dec 2021 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 443,703 420.2500 NSE
29 Dec 2021 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 443,703 420.1300 NSE
29 Dec 2021 ALPHA LEON ENTERPRISES LLP Bulk Sell 424,075 465.6900 NSE

All bulk and block deals →

Dividends

Full dividend history →
Last 12 months ₹1.00 per share
Dividend yield 0.11%
Ex-dateSubjectPer share (₹)Record date
4 Sep 2026 Dividend - Re 1 Per Share 1.0000 4 Sep 2026
4 Sep 2025 Dividend - Re 1 Per Share 1.0000 5 Sep 2025
20 Sep 2024 Annual General Meeting/Dividend - Rs 0.80 Per Share 0.8000 —
15 Sep 2023 Annual General Meeting/Dividend - Re 0.60 Per Share 0.6000 —
1 Sep 2022 Annual General Meeting/Dividend - Re 0.60 Per Share 0.6000 —

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
13 Aug 2026 Financial Results Yes
27 May 2026 Financial Results/Dividend Yes
9 Feb 2026 Financial Results Yes
12 Nov 2025 Financial Results Yes
13 Aug 2025 Financial Results Yes

Corporate Announcements

All 494 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
28 Sep 2026 Insider Trading / SAST Supriya Lifescience Ltd - 543434 - Closure of Trading Window
28 Sep 2026 Trading Window Supriya Lifescience Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
25 Sep 2026 Shareholders meeting Supriya Lifescience Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 24, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.
25 Sep 2026 AGM/EGM Supriya Lifescience Ltd - 543434 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
25 Sep 2026 AGM/EGM Supriya Lifescience Ltd - 543434 - Shareholder Meeting / Postal Ballot-Outcome of AGM
23 Sep 2026 General Updates Supriya Lifescience Limited has informed the Exchange about General Updates
23 Sep 2026 Reply to Clarification- Financial results The Exchange had sought clarification from Supriya Lifescience Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
20 Sep 2026 Analysts/Institutional Investor Meet/Con. Call Updates Supriya Lifescience Limited has informed the Exchange about Schedule of meet
11 Sep 2026 Company Update Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11 Sep 2026 Analysts/Institutional Investor Meet/Con. Call Updates Supriya Lifescience Limited has informed the Exchange about Schedule of meet

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.00)
  • Comfortable interest coverage (154.1x)
  • Strong revenue growth YoY (30.8%)

Weaknesses

  • Declining profit YoY (-30.9%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (38.5) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Supriya Lifescience Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.